Target intelligence / Profile preview

Vacuolar-type ATPase (V-ATPase)

Target
V-ATPase
Molecular classification
Enzyme, Ion transporter (proton pump), Rotary ATPase
01

Overview

Vacuolar-type ATPase (V-ATPase) is a large, multi-subunit rotary enzyme complex responsible for ATP-dependent proton (H⁺) transport across the membranes of various intracellular organelles (including lysosomes, endosomes, and the Golgi apparatus) and in certain cell types at the plasma membrane. The enzyme is essential for acidification of organellar lumens, which is required for protein degradation, membrane trafficking, and signaling events. Structurally, it contains two main domains: the V₁ domain (ATP hydrolysis) and the V₀ domain (proton translocation). V-ATPase dysfunction is linked to numerous human diseases, including cancer, bone, and renal disorders. While some bacterial V-type ATPases (notably Enterococcus hirae) can directly pump sodium (Na⁺) instead of protons, this function is not found in human V-ATPases, and dedicated sodium pumps in humans use P-type ATPases (Na⁺/K⁺-ATPase). Therefore, “sodium-pumping V-type ATPase” refers specifically to certain prokaryotic enzymes and is not standard nomenclature for a therapeutic target in humans.

Other names
Vacuolar H⁺-ATPaseV-ATPaseV-type ATPaseV₁V₀-ATPase
02

Mechanism of action

Inhibitors block ATP-hydrolysis–driven proton translocation, preventing organelle acidification and associated cellular processes.

03

Biological functions

Cellular pH homeostasis via organelle acidificationEndocytosis and vesicular traffickingProtein degradation through lysosomal acidificationRegulation of hormone secretion and neurotransmitter releaseIon and fluid homeostasismTOR and Notch signaling pathways
04

Disease associations

Cancer (proliferation, invasion, and metastasis)Renal tubular acidosisOsteopetrosis (bone disorders)Neurodegenerative diseases (indirect via lysosomal dysfunction)Infections (pathogen resistance and immune evasion)Other: generalized cellular pathologies related to endo-lysosomal dysfunction
05

Safety considerations

Ubiquitous expression and essential role in normal cell function pose challenge for therapeutic targeting; risk of toxicity to normal cellsNon-specific inhibition can disrupt general cellular acid-base homeostasis, leading to multi-organ dysfunction.
06

Interacting drugs

Bafilomycin A1 (classical research inhibitor, not used clinically)

3 more in the full profile.

07

Biomarkers

Lysosomal pH as a biomarker of activity/inhibition in cellsV-ATPase subunit expression levels in tumor tissues

Beyond the preview

Go deeper on Vacuolar-type ATPase (V-ATPase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolar-type ATPase (V-ATPase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call